A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers performed the first analysis of Jelmyto (UGN-101) to treat upper urinary tract urothelial cancers.
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.
